[Skip to Content]
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
May 26, 2015

Perioperative Use of β-Blockers in Cardiac and Noncardiac Surgery

Author Affiliations
  • 1Department of Internal Medicine 1—Cardiology, Linz General Hospital, Johannes Kepler University Linz School of Medicine, Austria
JAMA. 2015;313(20):2070-2071. doi:10.1001/jama.2015.1883

Clinical Question  Are β-blockers associated with lower rates of mortality and morbidity after cardiac or noncardiac surgery?

Bottom Line  In cardiac surgery, β-blockers are associated with a lower incidence of supraventricular tachycardias (SVTs) and ventricular arrhythmias. In noncardiac surgery, β-blockers are associated with a possible increase in mortality and strokes, a lower incidence of acute myocardial infarctions (AMIs) and SVTs, and an increase in bradycardia and hypotension. If tolerated, long-term β-blocker treatment should be continued perioperatively, whereas the decision to start a β-blocker should be individualized, weighing risks and benefits.